List of Studies ( Metabolite:GlcCer 18:1;O2/20:0)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Analysis Type |
|---|---|---|---|---|---|---|---|
| ST004163 | AN006911 | Targeted Lipid Profiling of HEK and iPSC derived iMG Cell Models with GBA1 Loss-of-Function | Cultured cells | Human | Metabolic disease | Denali Therapeutics | LC-MS |
| ST004163 | AN006911 | Targeted Lipid Profiling of HEK and iPSC derived iMG Cell Models with GBA1 Loss-of-Function | Cultured cells | Human | Parkinsons disease | Denali Therapeutics | LC-MS |
| ST004093 | AN006783 | Autoimmune Disease Risk Gene ANKRD55 Promotes T Cell Proliferation and Th17 2 Effector Function Through Metabolic Modulation | T-cells | Mouse | Autoimmune disease | Broad Institute of MIT and Harvard | LC-MS |
| ST004058 | AN006709 | Targeted Lipid and Metabolite Profiling in ATP13A2 knockout (KO) in HAP1 cells | Cultured cells | Human | Neurodegenerative disease | Denali Therapeutics | LC-MS |
| ST004058 | AN006709 | Targeted Lipid and Metabolite Profiling in ATP13A2 knockout (KO) in HAP1 cells | Cultured cells | Human | Parkinsons disease | Denali Therapeutics | LC-MS |
| ST003805 | AN006254 | Epigenetic changes, neuronal dysregulation and behavioral abnormalities in Zmym2+/- mutant mice, a genetic animal model of schizophrenia and neurodevelopmental disorders | Brain | Mouse | Neurodevelopment Disorder | Broad Institute of MIT and Harvard | LC-MS |
| ST003805 | AN006254 | Epigenetic changes, neuronal dysregulation and behavioral abnormalities in Zmym2+/- mutant mice, a genetic animal model of schizophrenia and neurodevelopmental disorders | Brain | Mouse | Schizophrenia | Broad Institute of MIT and Harvard | LC-MS |
| ST003438 | AN005649 | Unbiased genetic screening and metabolomics identifies glial adenosine metabolism as a therapeutic target in Parkinson’s disease | Fly Head | Fruit fly | Parkinsons disease | Broad Institute of MIT and Harvard | LC-MS |
| ST003215 | AN005272 | Protein restriction slows the development and progression of Alzheimer's disease in mice | Brain | Mouse | Alzheimers disease | University of Wisconsin-Madison | LC-MS |
| ST002195 | AN003593 | Untargeted lipidomics studies in the course of dermatitis onset and progression | Skin | Mouse | Dermatitis | Keio University | LC-MS |
| ST001964 | AN003202 | Quantitative genome-scale analysis of human liver reveals dysregulation of glycosphingolipid pathways in progressive nonalcoholic fatty liver disease | Blood | Human | Fatty liver disease | University of Turku | GC-MS |
| ST001289 | AN002142 | Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses | Macrophages | Mouse | LIPID MAPS | GC-MS/LC-MS | |
| ST001286 | AN002137 | Lipid composition of isolated lipid droplets from the functional bovine corpus luteum | Ovaries | Cow | University of Nebraska Medical Center | LC-MS | |
| ST001140 | AN001871 | Changes in the Canine Plasma Lipidome after Short- and Long-Term Excess Glucocorticoid Exposure | Blood | Dog | National University of Singapore;University of Zurich | LC-MS | |
| ST000917 | AN001501 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 3:Urine | Urine | Human | Fatty liver disease | LIPID MAPS | GC-MS/LC-MS |
| ST000916 | AN001495 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Plasma | Blood | Human | Fatty liver disease | LIPID MAPS | GC-MS/LC-MS |
| ST000915 | AN001489 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Liver | Liver | Human | Fatty liver disease | LIPID MAPS | GC-MS/LC-MS |
| ST000047 | AN000080 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (CSF) | Cerebrospinal fluid | Human | Alzheimers disease | Mayo Clinic | LC-MS |
| ST000005 | AN000012 | Timecourse on RAW 264.7 cells treated with Kdo2-Lipid A and compactin | Macrophages | Mouse | LIPID MAPS | GC-MS/LC-MS |